Natera (NTRA)
(Real Time Quote from BATS)
$91.40 USD
+0.12 (0.13%)
Updated Apr 26, 2024 11:14 AM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Natera (NTRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$99.81 | $123.00 | $70.00 | 9.34% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Natera comes to $99.81. The forecasts range from a low of $70.00 to a high of $123.00. The average price target represents an increase of 9.34% from the last closing price of $91.28.
Analyst Price Targets (16)
Broker Rating
Natera currently has an average brokerage recommendation (ABR) of 1.09 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.23 a month ago based on 15 recommendations.
Of the 16 recommendations deriving the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 87.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 13.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 12 | 12 | 12 |
Buy | 2 | 2 | 2 | 2 | 1 |
Hold | 0 | 0 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.09 | 1.09 | 1.23 | 1.23 | 1.18 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
4/8/2024 | Craig-Hallum | William B Bonello | Not Available | Strong Buy |
3/6/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
2/29/2024 | Canaccord Genuity | Kyle Mikson | Not Available | Strong Buy |
2/28/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
2/20/2024 | Raymond James | Andrew Cooper | Strong Buy | Moderate Buy |
1/30/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
12/29/2023 | BTIG | Mark Massaro | Not Available | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.09 |
ABR (Last week) | 1.09 |
# of Recs in ABR | 16 |
Average Target Price | $99.81 |
LT Growth Rate | NA |
Industry | Medical Services |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.72 |